The House Ways and Means Committee last night voted 24-17 to approve a revised version of the Lower Prescription Drug Costs Now Act (H.R. 3), legislation that would make a series of changes to the Medicare program in an effort to lower the price of prescription drugs.
 
The legislation would increase the number of single-source drugs from 25 to 35 that the Department of Health and Human Services would be required to negotiate directly with drug manufacturers. The bill, which was introduced last month, would, among other provisions, apply new inflationary rebates to Medicare Part B and Part D drugs that have had price increases above the rate of inflation since 2016; cap the Medicare Part D annual out-of-pocket limit at $2,000 and convert the current coverage gap into a benefit-wide responsibility; and realign the Medicare Part D catastrophic phase cost-sharing responsibilities.
 
The House Energy and Commerce Committee and Education and Labor Committee each approved similar versions of the bill last week.
 
The bills must be reconciled before they go to the House floor for a vote, which will likely be next week.

Related News Articles

Headline
President Trump today released his discretionary spending budget blueprint for fiscal year 2026. The “skinny budget” request, which includes top line…
Headline
The AHA April 30 released a report highlighting how hospitals and health systems continue to experience significant financial headwinds that can challenge…
Headline
The Supreme Court April 29 ruled 7-2 in favor of the Department of Health and Human Services in a case that challenged how HHS applied Congress’ formula for…
Headline
The House Energy and Commerce Committee held a markup April 29 where it advanced the AHA-supported SUPPORT Act (H.R. 2483). The legislation would reauthorize…
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription…
Headline
The Department of Commerce yesterday released notices announcing national security investigations on imports of pharmaceuticals, pharmaceutical ingredients and…